Avidity Unveils Promising Phase 1/2 Data on Del-zota for DMD44 Ahead of 2026 MDA Scientific Conference
Phase 1/2 Results Show Near-Normalization of CK Levels and Functional Gains
In a major development for the treatment of Duchenne muscular dystrophy (DMD44), Avidity Biosciences is set to spotlight 1-year data from its EXPLORE44 study at the upcoming 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. The oral session, scheduled for March 11, will feature insights from Dr. Craig McDonald of UC Davis, highlighting that Avidity’s RNA-based therapy, delpacibart zotadirsen (del-zota), achieved near normalization of creatine kinase (CK) levels and notable improvements in functional outcomes for DMD44 patients.
Diverse Research Portfolio with Seven Total Conference Presentations
Beyond the headline Phase 1/2 readout, Avidity will give one oral and six poster presentations, covering key findings across myotonic dystrophy and facioscapulohumeral muscular dystrophy, in addition to Duchenne. Notable topics include patient journeys, the impact of del-desiran on myotonic dystrophy, systematic reviews of disease burden in FSHD, and the mechanics of DUX4-driven dysregulation in muscle disease models.
| Session | Title | Disease/Area | Date |
|---|---|---|---|
| Oral | Del-zota Treatment: CK & Functional Improvement at 1 Year | DMD44 | March 11 |
| Poster | Patient Journey: Myotonic Dystrophy Type 1 (DM1) | DM1 | March 9 |
| Poster | Del-desiran Interviews – MARINA-OLE | DM1 | March 9 |
| Poster | DUX4 Regulation of KHDC1L in FSHD Models | FSHD | March 10 |
| Poster | Humanistic Burden of FSHD: Lit Review | FSHD | March 10 |
| Poster | SAFARI44 Phase 3 Study Design | DMD44 | March 9 |
| Poster | Inflammation/Fibrosis Signatures – EXPLORE44 RNASeq | DMD44 | March 8 |
Industry Forum to Highlight Biomarker Breakthroughs in Rare Disease
On March 10, Avidity will also host a lunch forum during the conference featuring discussions on biomarker advancements in treating rare neuromuscular diseases, with guest speakers from the University of Arkansas and Fred Hutchinson Cancer Center. This underscores industry collaboration and a focus on next-generation endpoints.
Targeted RNA Therapeutics Platform Leads Muscle Disease Innovation
Avidity’s Antibody Oligonucleotide Conjugate (AOC™) platform is a pioneering approach combining monoclonal antibody precision with oligonucleotide targeting, designed to enter muscle and other previously tough-to-reach tissues. The pipeline’s scope now spans rare muscle diseases (DMD, DM1, FSHD) and expanding initiatives in cardiomyopathies and immunological conditions, reinforced by partnerships and newly advanced wholly-owned candidates.
Key Takeaway: Upcoming Data May Validate Precision RNA Therapies
For physicians, researchers, and the wider healthcare community, Avidity’s MDA conference presentations will offer a critical look at how RNA-targeted treatments may shift the paradigm for debilitating muscle diseases. The 1-year EXPLORE44 data on del-zota—showing both significant biochemical and functional improvements—signals that next-generation RNA medicines could soon offer hope for conditions long considered untreatable.
All presentations and posters will be made available on Avidity’s website after the event. As clinical pipelines mature and more data emerges, stakeholders may benefit from tracking Avidity’s progress in both the scientific and investment landscapes.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI